【摘要】 醛糖还原酶是多元醇通路中的关键限速酶,高血糖浓度下,此通路代谢旺盛,与糖尿病并发症的发生和恶化有密切关系。醛糖还原酶抑制剂因此而成为糖尿病并发症的药物治疗因子,它主要是通过山梨醇通路降低体内血糖浓度,减少山梨醇在体内组织中的堆积达到治疗目的。目前已从植物、微生物中或化学合成获得了许多醛糖还原酶抑制剂,其中2个分别在日本和爱尔兰上市,还有部分正进行临床试验。现主要概述醛糖还原酶抑制剂筛选的研究进展。更多还原

【Abstract】 Aldose reductase is a key rate-limiting enzyme in polyol metabolic pathway.Hyperactivity of the pathway in individuals with high blood glucose level is closely related to the onset or progression of diabetic complications.Aldose reductase inhibitors have therefore been noted as pharmacotherapeutic agents for the treatment of diabetic complications.The aim of aldose reductase inhibitors therapy is to normalize the elevated flux of blood sugar and sorbitol through the polyol pathway in the target tissue.A large number of inhibitors have been obtained from plants and microorganisms or synthesis.Two of them have been on the market in Japan and Ireland,respectively,while some potent inhibitors are in clinical trials.This review mainly gives a breif account of the progress of research on screening of aldose reductase inhibitors.更多还原